This is the authors' abstract. We don't add key points for this paper.
We designed a series of pyrido[2,3- d ]pyrimidine derivatives based on the structure of the NEK6 kinase inhibitor, compound 21 (2-amino-5-phenyl-5,11-dihydro-3H-indeno[2′,1':5,6]pyrido[2,3- d ]pyrimidine-4,6-dione), which share the same heterocyclic core. Chemical modifications, aimed at altering the molecular planarity of 21 to enhance water solubility, were guided by receptor-based ligand design and further supported by molecular docking, molecular dynamics simulations, and free energy perturbation calculations. Our results indicate that disrupting the planarity of 21 increases aqueous solubility ― nearly doubling it in two cases― while reducing lipophilicity. Among the compounds tested, three showed both improved solubility and NEK6 inhibitory activity exceeding 50 % in single-dose assay. • Pyrido[2,3- d ]pyrimidine derivatives show promising profiles as NEK6 inhibitors. • The ring-opening strategy boosts solubility while retaining NEK6 activity. • FEP simulations and QSAR highlight key features to enhance NEK6 inhibitors' properties.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zardi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: